Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. The small intestine is the second predominant site of origin of GISTs. Ileal GISTs have a wide spectrum of clinical presentations, ranging from asymptomatic incidental nodules to acute abdominal pain, intestinal obstruction or tumor rupture with intra-abdominal hemorrhage [1,2]. On rare occasions, ileal GISTs can be diagnosed as an asymptomatic pelvic mass detected by chance through trans-vaginal ultrasound (TVU) and thus wrongly diagnosed as a mass of gynecologic origin. In literature 35 cases of ileal GISTs mimicking gynecologic masses have been described. We report five cases of female patients referred to our institution from March 2013 to January 2017, presenting with a pelvic mass at trans-vaginal ultrasound resulting, at final histologic examination, in an ileal GIST. We also describe in detail the trans-vaginal sonographic features.

Results

Characteristics of cases are listed in Table 1. Clinically, one patient was asymptomatic, and the mass was found during a routine gynecological consultation by TVU, two presented with abdominal pain, one with melena and one with left inguinal swelling. CA 125 was negative or mildly increased (< 170 U/ml) in all patients. TVU appearances of the pelvic mass are reported in Table 2. The lesions were mainly solid, inhomogeneous and hypoechoic in all cases (Figures 1 & 2). In four cases it was described as a “lobulated mass”. Cystic areas due to necrosis was described in one patient. No acoustic shadows were observed in all cases. The masses had no adhesion to the pelvic structures in three cases and were localized in the right pelvis mimicking a right ovarian lesion in four cases. All cases showed high vascularization at TVU (Figures 3 & 4).

In all cases a computed tomography (CT) scan showed a lobulated pelvic mass with contrast enhancement suggesting ovarian neoplasia. 18F-FDG PET/CT was performed in three patients: it showed a pathological up-take in one case only. In one case pelvic magnetic resonance imaging (MRI) was performed and confirmed the presence of a right adnexal mass. All patients underwent surgery in our Gynecologic Oncology Unit. A laparotomic ileal resection was performed in all cases. Hysterectomy and bilateral salpingo-oophorectomy were performed in two cases and left salpingo-oophorectomy in one. Pelvic peritonectomy and removal of peritoneal nodules and...
Omentum was necessary in two patients with advanced disease. Four patients achieved complete cytoreduction at the end of surgery.

The median size of the ileal GIST was 7.5 cm ranging from 6.5 cm to 17 cm. Histology confirmed infiltration of pelvic, abdominal, mesenteric and right diaphragmatic peritoneum and omentum in the patient with residual disease after surgery and bilateral ovarian metastases with infiltration of left Douglas pouch peritoneum in the other patient with advanced disease. All patients presented an intermediate or high risk of relapse according to Mittie’s classification. Imatinib at the standard dose of 400 mg daily was started in three patients however in two cases this was discontinued due to intolerance after a few months. One patient commenced a surveillance program due to the mutational status (any exon 8, 9, 11, 13, 17 exons KIT or 12, 14, 18 exons PDGFRA mutations).

Table 1: Patient characteristics.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Clinical presentation</th>
<th>Surgical management</th>
<th>Disease status</th>
<th>Size (cm)</th>
<th>Mitotic index</th>
<th>Molecular Analysis</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>31</td>
<td>Melena, anemia</td>
<td>Ileal resection</td>
<td>Localized</td>
<td>7.5</td>
<td>5/50 HPF</td>
<td>exon 11 KIT [c.1657_1668del (p.Y553_Q556)].</td>
<td>Alive without disease (OS = 49 months)</td>
</tr>
<tr>
<td>Case 2</td>
<td>77</td>
<td>Left inguinal swelling</td>
<td>Ileal resection, hysterectomy, bilateral salpingo-oophorectomy, asportation of peritoneal lumps</td>
<td>Advanced</td>
<td>17</td>
<td>9/50 HPF</td>
<td>exon 9 KIT [c.1509_1510insGCTA]</td>
<td>Dead</td>
</tr>
<tr>
<td>Case 3</td>
<td>53</td>
<td>Abdominal pain</td>
<td>Ileal resection, resection of ileal lump</td>
<td>Localized</td>
<td>8</td>
<td>5/50 HPF</td>
<td>KIT/PDGFRa WT</td>
<td>Alive without disease (OS: 16 months)</td>
</tr>
<tr>
<td>Case 4</td>
<td>76</td>
<td>Abdominal pain</td>
<td>Ileal resection, left salpingo-oophorectomy, omentectomy, ileal biopsies</td>
<td>Localized</td>
<td>6.5</td>
<td>&lt;5/50 HPF</td>
<td>exon 11 KIT (OS: 12 months)</td>
<td>Alive without disease</td>
</tr>
</tbody>
</table>

[p.V559D [c.1676T>A]].

In the patient with persistence of abdominal disease there was a mutation in KIT exon 9 and therefore Imatinib at the dose of 800 mg/daily was started but discontinued soon due to heart failure. This was then restarted at the reduced dose of 400 mg daily. At progression of the disease, a second line therapy with Sunitinib at the low dose of 25 mg/daily was started. This patient died of disease 44 months later. At the time of writing four patients are in follow-up alive without disease.
Conclusion

Ileal GISTs have a wide spectrum of clinical presentations, they can occasionally present as pelvic masses and wrongly be of gynecologic origin [3-11]. In this case series we tried to create some tips and advice to better recognize ileal GIST mimicking pelvic mass. From a sonographic point of view, after reviewing all images, we found some peculiar features: the mass frequently appeared solid, irregular, hypo-echoic, with small anechoic parts, without acoustic shadows, highly vascularized, frequently dislocated in the right pelvis mimicking a right ovarian neoplasia and the median diameter was 68 mm (Table 2). The pelvic mass had generally no signs of adhesions to other pelvic organs. The sonographic features of the cases previously reported in the literature are like those reported in our series [3-11].

Clinical presentation in our case series and in literature was heterogeneous and nonspecific and this does not permit differential diagnosis between GISTs and ovarian tumors. If we consider other cases described in literature [3-11], abdominal or pelvic pain is the most frequent symptom, probably due to the enlargement of the mass and compression of pelvic structures. In our limited experience radiological imaging (CT scan, pelvic MRI, 18F-FDG PET and TVU) were unable to define a GIST when it was in the pelvis. An abdominal and pelvic CT scan was the investment of choice for staging a GIST but lost specificity in diagnosis. Since the imaging diagnosis is based on the relationship of the mass to the wall of the gastrointestinal tract, in our experience we were unable to discriminate an adnexal mass from a GIST probably because in our cases a predominant extraluminal component was present.

18F-FDG PET is used mainly in the detection of tumor response to treatment because GISTs frequently demonstrate high 18F -FDG avidity but in our patients the avidity was high in only one case out of three.

These observations underline that in some cases the traditional radiological techniques may be inadequate in the identification of the origin of a GIST located in the pelvis whereas for ovarian masses TVU can be more useful than a CT scan for diagnosis and definition of the lesion. Moreover, we tried to identify other differences between GISTs and early stage ovarian cancer. Normal or mild serum levels of CA 125 (< 170 U/ml) and the absence of free fluid in the Douglas pouch can be considered ancillary features for suspicion of GIST.

After our analysis two issues arose; whether the pelvic GIST should be treated by a gynecologist or a general surgeon and what is the appropriate work-up in the case of suspected GIST.

Table 2: Ultra-sonographic features of our case series.

<table>
<thead>
<tr>
<th>Patient</th>
<th>US features</th>
<th>Size (mm)</th>
<th>Apparent origin</th>
<th>Vascularization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Multilocular solid mass with thick septa, 54x 27 mm and a 38x 30 mm solid component. No acoustic shadows.</td>
<td>84x 58x 69</td>
<td>Right ovary</td>
<td>Color Score 3</td>
</tr>
<tr>
<td>2</td>
<td>Solid, non-homogenous, hypoechoic, irregular pelvic mass not dissociable from neighboring structures</td>
<td>130x 120x 70</td>
<td>Right ovary</td>
<td>Color Score 4</td>
</tr>
<tr>
<td>3</td>
<td>Solid, lobulated mass with necrotic areas, hypomobile towards other pelvic structures</td>
<td>58x 47x 70</td>
<td>Right ovary</td>
<td>Color Score 4</td>
</tr>
<tr>
<td>4</td>
<td>Solid, lobulated, irregular; non-homogeneous with hyperechoic strands and hyperechoic nodules. Reduced mobility towards other structures.</td>
<td>57x 49x 66</td>
<td>Unknown</td>
<td>Color Score 4</td>
</tr>
<tr>
<td>5</td>
<td>Hypoechoic, lobulated, non-homogeneous, solid lesion. Preserved mobility from neighboring structures.</td>
<td>54x 37</td>
<td>Right ovary</td>
<td>Color Score 3</td>
</tr>
</tbody>
</table>

Summary of sonographic features:

Predominant solid, lobulated, non-homogeneous/hypoechoic mass. Possible presence of cystic areas (necrotic areas). No acoustic shadows. 68 mm (mean) Right ovary Color Score 3-4
Surgery of ileal GIST requires a gastrointestinal surgeon, but the role of a gynecologic surgeon can be relevant if GIST involves the genital tract and hysterectomy and salpingo-oophorectomy may be required. The principle of GIST surgery is the achievement of a complete excision of the disease with negative margins, avoiding intraoperative tumor rupture. Imatinib pre-operative treatment represents the standard of care in locally advanced GIST. In this context, histological examination by multiple core needle biopsies of the mass should be considered with the aim of achieving a histological diagnosis and the molecular status, necessary for medical treatment [12].

The hypothetical risk of cell seeding into the abdominal cavity and conversion of a local GIST into a disseminated one is present; however, the ESMO/European Sarcoma Network Working Group guidelines and the National Comprehensive Cancer Network guidelines of the United States of America accept the procedure if the biopsy is properly carried out in specialized centers. According to Eriksson et al., a preoperative diagnostic percutaneous biopsy of a suspected GIST did not increase the risk of GIST recurrence in a patient population who receive adjuvant Imatinib after biopsy [13]. Similarly, a trans-vaginal biopsy probably would not increase the risk of dissemination.

Moreover, a pre-operative diagnosis allows us to plan the appropriate surgical strategy for GIST and to avoid the risk of rupture during surgical manipulation, since it represents a validated poor prognostic factor [14]. Attention must be paid to the possibility of ovarian metastases from GIST that, even though rare, can occur [15]. We suggest that careful evaluation of both ovaries by TVU must be included in the pre-operative work-up as well as during follow-up. We invite gynecologists to consider a GIST in the case of atypical solid pelvic mass without a CA125 increase and ascites.

If GIST is suspected a surgical approach is suggested if complete removal of the disease is possible and if it does not require multi-visceral resection, otherwise pre-operative medical treatment is recommended. A gynecologic evaluation should be proposed in patients with a history of GIST because of the possibility of metastases to the genital tract. Increasing clinical records of GISTs mimicking pelvic masses have been reported, further collection and sharing of data is needed and the creation of a network between gynecologists, gastrointestinal surgeons and oncologists must be encouraged.

Acknowledgement

Conflict of interest the authors whose names are listed immediately below certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.

References
